I'm LongbridgeAI, I can summarize articles.Citi raised REMEGEN'starget price to HKD127.7 from HKD105, maintaining a Buy/High Risk rating. The upgrade follows a 433% YoY revenue surge in H1'26 and expected breakeven by FY2026 excluding BD income. Strong sales of telitacicept and disitamab vedotin, plus the RC148 deal, reshaped growth prospects. Citi increased revenue forecasts for 2026-28 by 3%, 22%, and 18%, lifting EPS estimates accordingly.
Citi said in a research report that REMEGEN (09995.HK) +0.450 (+0.560%) Short selling $22.93M; Ratio 6.403% 's revenue surged 433% YoY in 1H26, swinging from a loss to a profit of RMB4.66 billion. Management said that excluding BD income, net loss in 1H26 was about RMB26 million, and expected to achieve breakeven in FY2026 excluding BD income.
The broker said telitacicept and disitamab vedotin demonstrated strong QoQ sales growth, and believed the RC148 deal could reshape the company's growth trajectory. The broker raised its revenue forecasts for 2026-28 by 3%, 22% and 18%, and lifted its EPS forecasts to RMB8.5, RMB2.2 and RMB2.7 respectively. The TP was raised from HKD105 to HKD127.7, while the Buy/High Risk rating was maintained.(sl/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-26 12:25.)